Synaptogenix, Inc..
SNPX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Synaptogenix, Inc., a biopharmaceutical company, focuses on developing therapeutics for neurodegenerative diseases. Its lead drug candidate is Bryostatin-1, a protein kinase C epsilon (PKCe) activator, which is in Phase II clinical trials for the treatment of Alzheimer's disease. The company is also...Show More
Better Health for All
-10
Synaptogenix's lead drug candidate, Bryostatin-1, is in Phase 2 clinical trials for Alzheimer's disease.
1
While the overall trial failed to meet its primary endpoint, a severe cohort of Alzheimer's patients showed statistically significant and persistent benefits, with no significant cognitive decline over 10 months compared to a -12.8 SIB point decline in placebo patients.
2
Bryostatin-1 has also received Orphan Drug Designation from the FDA for Fragile X syndrome.
3
The drug has been tested in over 1,500 people in cancer studies, and the Phase 2 trial found it to be safe.
4
The Phase 2 trial was NIH-sponsored, receiving funding from the National Institute on Aging (NIA) and the National Cancer Institute (NCI).
5
The trial was a double-blind, randomized, placebo-controlled study that recruited 100 patients, randomized 1:1 to treatment or placebo.
6
Fair Money & Economic Opportunity
0
No evidence available to assess Synaptogenix, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data or information for any of the KPIs related to Fair Pay & Worker Respect, including living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
1
Fair Trade & Ethical Sourcing
0
Synaptogenix, Inc. is a biopharmaceutical company focused on drug development.
1
The provided articles explicitly state that information regarding fair trade and ethical sourcing metrics, including fair-trade certified spend, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, high-risk materials spend, and supplier diversity spend, is 'Not applicable' or 'N/A' for the company.
2
No regulatory actions, violations, fines, or compliance issues related to fair trade or ethical sourcing are mentioned in the reports.
3
Honest & Fair Business
-40
Synaptogenix, Inc. has a formal whistleblower protection policy that includes a hotline for confidential and anonymous reporting and an anti-retaliation pledge for reporting violations in good faith.
1
However, there is no evidence regarding independent investigation processes, training, or effectiveness metrics for this policy.
2
The company also has an FCPA-compliant anti-corruption policy with explicit prohibitions against bribery, gifts to foreign officials, and improper influence of government officials.
3
The available information does not detail the frequency of training for this policy or provide metrics on its effectiveness.
4
Kind to Animals
0
No evidence was found in the provided articles regarding Synaptogenix, Inc.'s (SNPX.US) performance on any of the 'Kind to Animals' KPIs. The articles either focused on the company's financial and clinical trial information without mentioning animal welfare, or discussed general industry trends and other companies' efforts in animal-free research without specific data pertaining to Synaptogenix.
No War, No Weapons
0
No evidence available to assess Synaptogenix, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Synaptogenix, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No relevant data was found in the provided article to assess Synaptogenix, Inc. against the 'Respect for Cultures & Communities' value.
1
The article URL resulted in a 404 error, indicating no information could be extracted.
2
Safe & Smart Tech
0
The provided articles focus exclusively on Synaptogenix's financial activities, including its investment strategy in AI tokens (TAO) and funding rounds. No information is available regarding the company's data protection, cybersecurity measures, AI ethics governance, privacy practices, or any related incidents. Therefore, no KPIs under the 'Safe & Smart Tech' value can be scored based on the evidence provided.
Zero Waste & Sustainable Products
0
No evidence available to assess Synaptogenix, Inc. on Zero Waste & Sustainable Products.